Altered sphingoid base profiles in type 1 compared to type 2 diabetes

Lipids in Health and Disease

Florian S Eichler⁵  Thorsten Hornemann¹  Irina Alecu¹  Alaa Othman¹  Rodica Pop-Busui²  Jessica Pan⁴  Nancy Wei³ 

[1] Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100, Zürich 8091, Switzerland;Department of Internal Medicine, Metabolism Endocrinology and Diabetes, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA;Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA;MGH Neuroscience Center, Department of Neurology, Harvard Medical School, 55 Fruit Street ACC 708, Boston, MA 02114, USA;Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, ACC 708, Boston, MA 02114, USA

关键词: Type 1 diabetes mellitus;    Type 2 diabetes mellitus;    Metabolic syndrome;    Deoxysphingolipids;    Biomarker;    Atypical sphingolipids;   

Others  :  1151815
DOI  :  10.1186/1476-511X-13-161

 received in 2014-05-20, accepted in 2014-09-27,  发布年份 2014

【 摘 要 】

Background

Sphingolipids are increasingly recognized to play a role in insulin resistance and diabetes. Recently we reported significant elevations of 1-deoxysphingolipids (1-deoxySL) - an atypical class of sphingolipids in patients with metabolic syndrome (MetS) and diabetes type 2 (T2DM). It is unknown whether 1-deoxySL in patients with diabetes type 1 (T1DM) are similarly elevated.

Findings

We analyzed the long chain base profile by LC-MS after hydrolyzing the N-acyl and O-linked headgroups in plasma from individuals with T1DM (N = 27), T2DM (N = 30) and healthy controls (N = 23). 1-deoxySLs were significantly higher in the groups with T2DM but not different between T1DM and controls. In contrast to patients with T2DM, 1-deoxSL levels are not elevated in T1DM.

Conclusions

Our study indicates that the 1-deoxySL formation is not per-se caused by hyperglycemia but rather specifically associated with metabolic changes in T2DM, such as elevated triglyceride levels.

【 授权许可】

   
2014 Wei et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Cowart LA: Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009, 20:34-42.
• [2]Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, Bandyopadhyay S, Jones KN, Kelly S, Shaner RL, Sullards CM, Wang E, Murphy RC, Barkley RM, Leiker TJ, Raetz CR, Guan Z, Laird GM, Six DA, Russell DW, McDonald JG, Subramaniam S, Fahy E, Dennis EA: Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010, 51:3299-3305.
• [3]Penno A, Reilly MM, Houlden H, Laura M, Rentsch K, Niederkofler V, Stoeckli ET, Nicholson G, Eichler F, Brown RH Jr, von Eckardstein A, Hornemann T: Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 2010, 285(15):11178-11187.
• [4]Eichler F, Hornemann T, McCampbell A, Kuljis D, Penno A, Vardeh D, Tamrazian E, Garofalo K, Lee H, Kini L, Selig M, Frosch M, Gable K, von Eckardstein A, Woolf CJ, Guan G, Harmon JM, Dunn TM, Brown RH: Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J Neurosci 2010, 29(46):14646-14651.
• [5]Auer-Grumbach M: Hereditary sensory neuropathy type I. Orphanet J Rare Dis 2008, 3:7. BioMed Central Full Text
• [6]Othman A, Rütti MF, Ernst D, Saely CH, Rein P, Drexel H, Porretta-Serapiglia C, Lauria G, Bianchi R, von Eckardstein A, Hornemann T: Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 2012, 55:421-431.
• [7]Bertea M, Rütti MF, Othman A, Marti-Juan J, Hersberger M, Von Eckardstein A, Hornemann T: Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis 2010, 9:84. BioMed Central Full Text
• [8]Hornemann T, Penno A, Rütti MF, Ernst D, Kivrak-Pfiffner F, Rohrer L, Von Eckardstein A: The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. J Biol Chem 2009, 284:26322-26330.
• [9]Zitomer NC, Mitchell T, Voss KA, Bondy GS, Pruett ST, Garnier-Amblard EC, Liebeskind LS, Park H, Wang E, Sullards MC, Merrill AH Jr, Riley RT: Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxy-sphinganine: a novel category of bioactive 1-deoxy-sphingoid bases and 1-deoxy-dihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem 2009, 284:4786-4795.